Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SHE:002603)
China · Delayed Price · Currency is CNY 15.20
+0.08 (0.53%)
Sep 18, 2026, 3:04 PM CST
SHE:002603 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 25,395 | 28,519 | 26,748 | 38,543 | 50,054 | 32,746 | |
Market Cap Growth | -9.63% | 6.62% | -30.60% | -23.00% | 52.86% | 7.84% |
Enterprise Value | 23,293 | 26,598 | 27,105 | 38,844 | 48,806 | 32,890 |
Last Close Price | 15.20 | 16.53 | 15.24 | 21.55 | 27.43 | 17.73 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 18.47 | 22.17 | - | 28.50 | 21.19 | 24.37 |
Forward PE | 16.89 | 21.57 | 18.07 | 16.45 | 27.48 | 15.62 |
PS Ratio | 3.23 | 3.64 | 4.11 | 3.74 | 3.99 | 3.24 |
PB Ratio | 2.33 | 2.60 | 2.62 | 3.37 | 4.58 | 3.61 |
P/TBV Ratio | 2.57 | 2.83 | 2.87 | 3.64 | 4.90 | 3.89 |
P/FCF Ratio | 13.64 | 18.63 | 83.43 | - | 15.29 | - |
P/OCF Ratio | 11.95 | 16.05 | 43.78 | 247.93 | 14.35 | 61.94 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.96 | 3.40 | 4.16 | 3.77 | 3.89 | 3.25 |
EV/EBITDA Ratio | 10.04 | 11.98 | - | 18.04 | 14.82 | 17.58 |
EV/EBIT Ratio | 13.94 | 16.57 | - | 24.08 | 17.10 | 21.66 |
EV/FCF Ratio | 12.51 | 17.37 | 84.54 | - | 14.91 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.12 | 0.08 | 0.14 |
Debt / EBITDA Ratio | 0.01 | 0.01 | - | 0.66 | 0.26 | 0.65 |
Debt / FCF Ratio | 0.01 | 0.02 | 0.08 | - | 0.27 | - |
Net Debt / Equity Ratio | -0.19 | -0.17 | -0.08 | 0.02 | -0.14 | 0.02 |
Net Debt / EBITDA Ratio | -0.91 | -0.83 | 3.51 | 0.13 | -0.47 | 0.10 |
Net Debt / FCF Ratio | -1.12 | -1.20 | -2.58 | -1.75 | -0.47 | -1.23 |
Asset Turnover | 0.56 | 0.58 | 0.43 | 0.62 | 0.86 | 0.83 |
Inventory Turnover | 1.79 | 1.78 | 1.66 | 1.98 | 2.47 | 2.28 |
Quick Ratio | 1.54 | 1.60 | 0.91 | 0.84 | 0.95 | 1.15 |
Current Ratio | 2.20 | 2.36 | 1.66 | 1.47 | 1.50 | 1.89 |
Return on Equity (ROE) | 12.62% | 12.10% | -6.78% | 12.02% | 23.57% | 14.91% |
Return on Assets (ROA) | 7.49% | 7.43% | -3.45% | 6.05% | 12.20% | 7.78% |
Return on Invested Capital (ROIC) | 15.17% | 13.96% | -7.94% | 12.21% | 25.97% | 15.53% |
Return on Capital Employed (ROCE) | 14.70% | 14.00% | -7.80% | 12.90% | 24.80% | 15.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 5.42% | 4.51% | -2.71% | 3.51% | 4.72% | 4.10% |
FCF Yield | 7.33% | 5.37% | 1.20% | -0.40% | 6.54% | -0.44% |
Dividend Yield | 5.26% | 4.84% | - | 1.39% | 1.82% | 1.69% |
Payout Ratio | 97.19% | 38.96% | - | 64.54% | 11.96% | 90.79% |
Buyback Yield / Dilution | -0.02% | -0.01% | 0.01% | 0.01% | -0.01% | 0.00% |
Total Shareholder Return | 5.24% | 4.83% | 0.01% | 1.40% | 1.82% | 1.69% |